BREAKWATER队列3:encorafenib联合西妥昔单抗及FOLFIRI对比FOLFIRI±贝伐珠单抗治疗BRAF V600E突变型结直肠癌的随机研究
BREAKWATER队列3纳入147例既往未治疗的BRAF V600E突变型转移性结直肠癌患者,随机接受EC+FOLFIRI或FOLFIRI±贝伐珠单抗。EC+FOLFIRI显著提高BICR评估的ORR(64.4% vs 39.2%)并延长PFS(15.2 vs 8.3个月)和OS,安全性总体可控。
要点
- EC+FOLFIRI较对照组显著提高ORR(64.4% vs 39.2%,OR=2.756)。
- EC+FOLFIRI显著改善PFS(HR=0.44,15.2 vs 8.3个月)。
- EC+FOLFIRI观察到OS延长(HR=0.56),支持其作为新标准治疗选择。
核心结论
- EC+FOLFIRI在BRAF V600E突变型mCRC中较对照组显著改善ORR和PFS,并延长OS,安全性总体可控。
- 这些数据支持EC+FOLFIRI作为BRAF V600E突变型mCRC的附加新标准治疗,实现治疗个体化。
研究设计与样本
- BREAKWATER队列3为随机研究,纳入既往未治疗的BRAF V600E突变型mCRC患者147例。
- 患者按1:1随机分配至EC+FOLFIRI组(n=73)或FOLFIRI±贝伐珠单抗对照组(n=74)。
- 主要终点为BICR评估的ORR,关键次要终点为BICR评估的PFS,其他次要终点包括OS和安全性。
主要发现
- EC+FOLFIRI组BICR评估的ORR为64.4%,对照组为39.2%(OR=2.756,95%CI 1.420-5.348,单侧P=0.0011)。
- EC+FOLFIRI组BICR评估的PFS为15.2个月,对照组为8.3个月(HR=0.44,95%CI 0.27-0.70,单侧P=0.0002)。
- EC+FOLFIRI组观察到OS延长(HR=0.56,95%CI 0.34-0.94,EC+FOLFIRI组不可估计 vs 对照组20.3个月)。
- EC+FOLFIRI组严重不良事件发生率为49.3%,对照组为44.1%。
- 安全性特征与各药物已知特征一致,未观察到新的安全性信号。
临床怎么用
- 对于既往未治疗的BRAF V600E突变型mCRC患者,可考虑EC+FOLFIRI作为新的标准治疗选择。
- 治疗决策中需结合ORR、PFS和OS获益以及安全性特征进行个体化选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Encorafenib + cetuximab (EC) and mFOLFOX6 or irinotecan, leucovorin, and fluorouracil (FOLFIRI) is approved in several countries for BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on results from the BREAKWATER trial. PATIENTS AND METHODS: In BREAKWATER Cohort 3, eligible patients with previously untreated BRAF V600E-mutant mCRC were randomly assigned 1:1 to receive EC+FOLFIRI or FOLFIRI with or without bevacizumab (control). The primary endpoint was objective response rate (ORR) by blinded independent central review (BICR), and the key secondary endpoint was progression-free survival (PFS) by BICR. Other secondary endpoints included overall survival (OS) and safety. RESULTS: A total of 147 patients were randomly allocated in Cohort 3 (EC+FOLFIRI, n = 73; control, n = 74) with similar baseline demographics and disease characteristics across arms. EC+FOLFIRI demonstrated clinically meaningful and statistically significant improvement in ORR by BICR {64.4% versus 39.2%, odds ratio = 2.756 [95% confidence interval (CI) 1.420-5.348], one-sided P-value = 0.0011}, meeting the primary endpoint (1 March 2025, data cutoff). At the 6 January 2026 data cutoff, the key secondary endpoint was met, with EC+FOLFIRI demonstrating a clinically meaningful and statistically significant PFS [hazard ratio = 0.44 (95% CI 0.27-0.70), one-sided P-value = 0.0002, 15.2 versus 8.3 months]. Prolonged OS was also observed with EC+FOLFIRI (hazard ratio = 0.56 [95% CI 0.34-0.94], not estimable versus 20.3 months). Serious adverse event rates were 49.3% versus 44.1% for the EC+FOLFIRI versus control arms, respectively. The safety profile was consistent with that known for each agent. CONCLUSIONS: EC+FOLFIRI demonstrated clinically meaningful and statistically significant improvements in ORR and PFS, with prolonged OS versus control in BRAF V600E-mutant mCRC. The safety profile was generally manageable, with no new safety signals. These data support EC+FOLFIRI as an additional new standard of care for patients with BRAF V600E-mutant mCRC, enabling treatment personalisation.
引用
- Kopetz S, Tabernero J, Lonardi S, et al. A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3. Ann Oncol. 2026. PMID: 42219860. doi:10.1016/j.annonc.2026.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。